- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04136912
3-D Super Resolution Ultrasound Microvascular Imaging
High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Carly Sronce
- Phone Number: 9199663262
- Email: carly_sronce@med.unc.edu
Study Contact Backup
- Name: Desma Jones, CCRC
- Phone Number: 9198439463
- Email: desma_jones@med.unc.edu
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- Univeristy of North Carolina Chapel Hill
-
Contact:
- Desma Jones, CCRC
- Phone Number: 9198439463
- Email: desma_jones@med.unc.edu
-
Contact:
- Carly Sronce
- Phone Number: 919-966-3262
- Email: carly_sronce@med.unc.edu
-
Principal Investigator:
- Yueh Lee, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Healthy Volunteers
Inclusion Criteria
- Able to provide informed consent
- Negative urine pregnancy test in women of child-bearing potential
Exclusion Criteria
- Institutionalized subject (prisoner or nursing home patient)
- Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD)
- Known hypersensitivity to perflutren lipid (Definity®)
Active cardiac disease including any of the following:
- Severe congestive heart failure
- Unstable angina.
- Severe arrhythmia
- Myocardial infarction within 14 days prior to the date of proposed Definity® administration.
- Pulmonary hypertension
- Cardiac shunts
Breast Imaging Patients
Inclusion Criteria
- Women
- Patient had a diagnostic breast ultrasound study performed at UNC
- Scheduled for a core needle or surgical breast biopsy of at least one breast lesion that is 2 cm or less in size and 3 cm in depth from the skin surface
- Able to provide informed consent
- Negative urine pregnancy test in women of child-bearing potential
- BIRADS score of 4 or 5.
Exclusion Criteria
- Male
- Institutionalized subject (prisoner or nursing home patient)
- Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD)
- Sonographically visible breast lesion larger than 2cm or greater than 3cm in depth from the skin surface
- Known hypersensitivity to perflutren lipid (Definity®)
Active cardiac disease including any of the following:
- Severe congestive heart failure
- Unstable angina.
- Severe arrhythmia
- Myocardial infarction within 14 days prior to the date of proposed Definity® administration.
- Pulmonary hypertension
- Cardiac shunts
Thyroid Imaging Patients Inclusion Criteria
- Patient had a diagnostic thyroid ultrasound study performed at UNC
- TIRADS risk score of 4c or 5
- Scheduled for a core needle or surgical thyroid biopsy, fine needle aspiration, or thyroidectomy of at least one sonographically visible thyroid lesion that is 3 cm in depth from the skin surface
- Able to provide informed consent
- Negative urine pregnancy test in women of child-bearing potential
Exclusion Criteria
- Institutionalized subject (prisoner or nursing home patient)
- Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD)
- Known hypersensitivity to perflutren lipid (Definity®)
Active cardiac disease including any of the following:
- Severe congestive heart failure
- Unstable angina.
- Severe arrhythmia
- Myocardial infarction within 14 days prior to the date of proposed Definity® administration.
- Pulmonary hypertension
- Cardiac shunts
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Breast Imaging Cohort
A total of 15 women with known breast lesions that are already scheduled to undergo a clinical biopsy
|
Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information.
When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
Other Names:
Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8). Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. |
Experimental: Thyroid Imaging Cohort
A total of 15 participants with known thyroid lesions that are already scheduled to undergo a clinical biopsy
|
Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information.
When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
Other Names:
Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8). Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. |
Experimental: Healthy Volunteers Cohort
A total of 15 participants will be included to optimize imaging parameters.
|
Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information.
When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
Other Names:
Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8). Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of Acoustic Angiography; Breast Imaging (percent of positive scans)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
Sensitivity of Acoustic Angiography in the analysis of know breast lesions will be evaluated by comparing image analyses to the pathological results for these lesions.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Specificity of Acoustic Angiography; Breast Imaging (percent of negative scans)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
Specificity of Acoustic Angiography in the analysis of know breast lesions will be evaluated by comparing image analyses to the pathological results for these lesions.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Sensitivity of Acoustic Angiography; Thyroid Imaging (percent of positive scans)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
Sensitivity of Acoustic Angiography in the analysis of know thyroid lesions will be evaluated by comparing image analyses to the pathological results for these lesions.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Specificity of Acoustic Angiography; Thyroid Imaging (percent of negative scans)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
Specificity of Acoustic Angiography in the analysis of know thyroid lesions will be evaluated by comparing image analyses to the pathological results for these lesions.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Curve of Acoustic Angiography (arbitrary units)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
To compare the area under the curve (AUC) of acoustic angiography to the AUC of the b-mode ultrasound
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Radiologist preference (Arbitrary units)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
To compare radiologist preference of acoustic angiography to conventional b-mode ultrasound for each lesion characteristic (shape, margins, and vascularity)
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Sensitivity of acoustic angiography compared to conventional ultrasound: Breast (arbitrary units)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
To compare (using a reader study) the sensitivity of acoustic angiography to the sensitivity of conventional b-mode ultrasound in evaluation of known breast lesions for predicting malignancy.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Specificity of acoustic angiography compared to conventional ultrasound: Breast (arbitrary units)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
To compare (using a reader study) the specificity of acoustic angiography to the specificity of conventional b-mode ultrasound in evaluation of known breast lesions for predicting malignancy.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Sensitivity of acoustic angiography compared to conventional ultrasound: Thyroid (arbitrary units)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
To compare (using a reader study) the sensitivity of acoustic angiography to the sensitivity of conventional b-mode ultrasound in evaluation of known thyroid lesions for predicting malignancy.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Specificity of acoustic angiography compared to conventional ultrasound: Thyroid (arbitrary units)
Time Frame: Calculated once all imaging is complete [Anticipated 1.5 years]
|
To compare (using a reader study) the specificity of acoustic angiography to the specificity of conventional b-mode ultrasound in evaluation of known thyroid lesions for predicting malignancy.
|
Calculated once all imaging is complete [Anticipated 1.5 years]
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yueh Lee, MD, PhD, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC1915
- R01CA220681 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Definity
-
University of VirginiaCompletedType 1 DiabetesUnited States
-
Lantheus Medical ImagingSyneos HealthCompletedCardiac DiseaseUnited States
-
Mayo ClinicLantheus Medical ImagingCompletedMyocardial Perfusion ImagingUnited States
-
Lantheus Medical ImagingCompletedCardiovascular DiseaseUnited States
-
E. Peden, MDThe Methodist Hospital Research Institute; Lantheus Medical ImagingCompleted
-
Thomas Jefferson UniversityRothman Institute Orthopaedics; Lantheus Medical ImagingCompletedChronic Exertional Compartment SyndromeUnited States
-
Thomas Jefferson UniversityAmerican Heart Association; Lantheus Medical ImagingCompletedHeart Failure | Blood Pressure | Cardiac Catheterization | Echocardiography | Heart VentriclesUnited States
-
University Health Network, TorontoLantheus Medical ImagingCompleted
-
University of VirginiaTerminatedInflammatory Bowel DiseaseUnited States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)UnknownContrast Induced Acute Kidney InjuryUnited States